Literature DB >> 6092723

Analysis of three late varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3.

A Vafai, Z Wroblewska, M Wellish, M Green, D Gilden.   

Abstract

Two monoclonal antibodies were prepared against varicella-zoster virus proteins. One of the monoclonal antibodies (10.2) reacted only with the nuclei of infected cells and immunoprecipitated one nonglycosylated late viral protein (125,000 molecular weight). The other monoclonal antibody (19.1) with neutralizing activity, reacted with membrane antigens of infected cells and with the varicella-zoster virus envelope and immunoprecipitated two late major viral glycoproteins (gp1 and gp3). Synthesis of the 125,000-molecular-weight protein, gp1, and gp3 began at 20 to 22 h postinfection, 2 h after the peak of viral DNA synthesis, and continued until 29 h postinfection, when the first progeny virus appeared in infected cells. Pulse-chase experiments showed that during pulse-labeling, only gp1 was detected, whereas during the chase period, gp1 as well as gp3 was detected in infected cells. Under nonreducing conditions, gp3 migrated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a 130,000-molecular-weight protein as compared with the 62,000-molecular-weight species obtained when gels were resolved under reducing conditions. This finding indicates that gp3 is a dimer that is disulfide linked.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092723      PMCID: PMC254619     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Varicella-zoster virus infection of human brain cells and ganglion cells in tissue culture.

Authors:  D H Gilden; Z Wroblewska; V Kindt; K G Warren; J S Wolinsky
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

3.  The proteins of varicella-zoster-virus.

Authors:  M H Wolff
Journal:  Med Microbiol Immunol       Date:  1978-11-17       Impact factor: 3.402

4.  Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate.

Authors:  G M Wahl; M Stern; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

5.  Deoxyribonucleic acid synthesis in synchronized mammalian KB cells infected with herpes simplex virus.

Authors:  G H Cohen; R K Vaughan; W C Lawrence
Journal:  J Virol       Date:  1971-06       Impact factor: 5.103

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Isolation and polypeptide characterization of varicella-zoster virus.

Authors:  Y Shemer; S Leventon-Kriss; I Sarov
Journal:  Virology       Date:  1980-10-15       Impact factor: 3.616

8.  The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus.

Authors:  C Grose
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

9.  Studies on the polypeptides of varicella-zoster (V-Z) virus. 1. Detection of varicella-zoster virus polypeptides in infected cells.

Authors:  Y Asano; M Takahashi
Journal:  Biken J       Date:  1979-09

10.  Herpes simplex virus resistance and sensitivity to phosphonoacetic acid.

Authors:  R W Honess; D H Watson
Journal:  J Virol       Date:  1977-02       Impact factor: 5.103

View more
  12 in total

1.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

2.  Postentry events are responsible for restriction of productive varicella-zoster virus infection in Chinese hamster ovary cells.

Authors:  Renée L Finnen; Kara R Mizokami; Bruce W Banfield; Guang-Yun Cai; Scott A Simpson; Lewis I Pizer; Myron J Levin
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products.

Authors:  A J Davison; C M Edson; R W Ellis; B Forghani; D Gilden; C Grose; P M Keller; A Vafai; Z Wroblewska; K Yamanishi
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

4.  Antigens of infectious laryngotracheitis herpesvirus defined by monoclonal antibodies.

Authors:  J J York; S Sonza; M R Brandon; K J Fahey
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV.

Authors:  A Vafai; W N Yang
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

6.  Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus.

Authors:  J Davies; J A Hallworth; P McLeish; S Randall; B A Martin; A Buchan; G R Skinner
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

7.  Localization of varicella-zoster virus gene 21 protein in virus-infected cells in culture.

Authors:  R Mahalingam; R Lasher; M Wellish; R J Cohrs; D H Gilden
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies.

Authors:  A Vafai; Z Wroblewska; R Mahalingam; G Cabirac; M Wellish; M Cisco; D Gilden
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia.

Authors:  A Vafai; M Wellish; D H Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Expression of varicella-zoster virus and herpes simplex virus in normal human trigeminal ganglia.

Authors:  A Vafai; R S Murray; M Wellish; M Devlin; D H Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.